【摘要】 目的:探讨短期应用替格瑞洛在急性冠状动脉综合征(ACS)患者中的治疗作用。方法:选择ACS患者107例,随机分为替格瑞洛组(A组,50例)和氯吡格雷组(B组,57例),收集2组临床资料,并监测服药前和服药后2 h、4 h、24 h、7 d、30 d的血小板聚集率,记录入院30 d内2组主要不良心血管事件和主要不良反应。结果:A组患者用药后血小板聚集率在2 h、4 h、24 h、7 d和30 d时均低于B组(P<0.05~P<0.01),2组患者用药后不同时间血小板聚集率均显著低于用药前(P<0.01)。2组患者主要不良心血管事件发生率及不良反应发生率差异均无统计学意义(P>0.05)。结论:对于ACS患者,替格瑞洛抑制血小板优于氯吡格雷,且疗效更平稳,两者安全性相似。更多还原

【Abstract】 Objective: To explore the therapeutic effects of ticagrelor on the patients with acute coronary syndrome( ACS). Methods:One hundred and seven ACS patients were randomly divided into the ticagrelor group( group A,50 cases) and clopidogrel group( group B,57 cases). The clinical data of two groups were collected. The platelet aggregation rates in two groups were detected before and after2 h,4 h,24 h,7 d and 30 d of medicine. The major adverse reaction and adverse cardiac event within 30 days were observed. Results:The platelet aggregation rates in group A after 2 h,4 h,24 h,7 d and 30 d of medicine were significantly lower than that in group B( P < 0. 05 to P < 0. 01),and the platelet aggregation rates in two groups before medicine were significantly lower than that in different time points after medicine( P < 0. 01). The differences of the incidences of major adverse reaction and adverse cardiac event between two groups were not statistically significant( P > 0. 05). Conclusions: The effect of the ticagrelor in inhibiting platelet in patients with ACS is better than that of clopidogrel,and the securities of two are similar.更多还原